Characterization of latent HCMV viral load and immunological parameters in adult epilepsy patients receiving pharmacological therapy

Characterization of latent HCMV viral load and immunological parameters in adult epilepsy patients receiving pharmacological therapy - EpiVir

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040416

Enrollment

450

Registered

2026-05-21

Start date

2026-05-20

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B25.9 G40.9

Interventions

Group 1: The study will include 450 patients who have been diagnosed with epilepsy and have been on stable therapy with antiepileptic drugs for at least one year. A single blood sample will be collect

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosed epilepsy under stable treatment for more than one year.

Exclusion criteria

Exclusion criteria: - Immunosuppressive therapy (e.g., steroids, anti-TNF agents, chemotherapy) - History of organ transplantation

Design outcomes

Primary

Measure	Time frame
Investigation of HCMV DNA levels in monocytes in patients with diagnosed and treated epilepsy.	—

Countries

Germany

Contacts

Public ContactSebastian Voigt

Institut für Virologie, Universitätsklinikum Essen

sebastian.voigt@uk-essen.de+492017232306

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026